ALKBH5 and acute myeloid leukemia: Another ALKBH5 inhibitor, DDO-2728, has been demonstrated to increase the abundance of m6A modifications in AML cells and inhibit cell cycle progression via a reduction in the mRNA stability of TATC3 [128].